InspireMD Inc
NASDAQ:NSPR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.85
3.39
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
InspireMD Inc
InspireMD Inc
Cost of Revenue
InspireMD Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
InspireMD Inc
NASDAQ:NSPR
|
Cost of Revenue
-$5.3m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-9%
|
|
|
N
|
Nissan Medical Industries Ltd
TASE:NISA
|
Cost of Revenue
-₪582.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
A
|
Allmed Solutions Ltd
TASE:ALMD
|
Cost of Revenue
₪0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
InspireMD Inc
Glance View
InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
See Also
What is InspireMD Inc's Cost of Revenue?
Cost of Revenue
-5.3m
USD
Based on the financial report for Sep 30, 2024, InspireMD Inc's Cost of Revenue amounts to -5.3m USD.
What is InspireMD Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-9%
Over the last year, the Cost of Revenue growth was -33%. The average annual Cost of Revenue growth rates for InspireMD Inc have been -18% over the past three years , -13% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
